Progenics Pharmaceuticals (PGNX) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 2 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Progenics Pharmaceuticals (PGNX) stock is expected to deviate a maximum of $3.54 from the average target price of $11.5 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $14 and the most muted being $9.
Progenics Pharmaceuticals (NASDAQ:PGNX): After opening at $6.11, the stock dipped to an intraday low of $6.02 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.26 and the buying power remained strong till the end. The stock closed at $6.22 for the day, a gain of 1.63% for the day session. The total traded volume was 873,745. The stocks close on the previous trading day was $6.12.
Progenics Pharmaceuticals, Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).